# Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)

> **NCT05374915** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Kintara Therapeutics, Inc.** · enrollment: 15 (estimated)

## Conditions studied

- Cutaneous Breast Cancer

## Interventions

- **COMBINATION_PRODUCT:** REM-001 photodynamic therapy

## Key facts

- **NCT ID:** NCT05374915
- **Lead sponsor:** Kintara Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-02-12
- **Primary completion:** 2025-12-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05374915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05374915, "Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05374915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*